Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026

Savara (Nasdaq: SVRA) announced accepted molgramostim presentations for CHEST 2026, taking place October 18–21 in Phoenix, Arizona.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

-- Company to Host Learning Theatre on aPAP with Renowned Key Opinion Leader Along with Members of the Patient Community --

YARDLEY, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of an encore oral presentation on data from the Phase 3 IMPALA-2 clinical trial and a poster presentation on data from the Phase 2/3 IMPALA clinical trial at CHEST 2026 in Phoenix, Arizona, October 18–21.

Oral Presentation

Title: Long-Term Efficacy and Safety of Molgramostim in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP): Results From the IMPALA-2 Trial Open-Label Treatment Period
Session ID: 4175, ILD Treatment Updates
Date/Time: Tuesday, October 20, 2026, 1:45 – 2:30 PM MST
Location: Phoenix Convention Center, Arizona (Exhibit Hall Rapid Fire Area 2D)
Presenter: Bruce C. Trapnell, M.D., Professor of Medicine and Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, U.S.

Poster Presentation

Title: Molgramostim Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis Patients with Mild Diffusion Impairment
Poster Number: 4315
Session: Diffuse Lung Disease Scientific Abstract Posters: Idiopathic ILD, Orphan Lung Disease, Sarcoidosis
Date/Time: Wednesday, October 21, 2026, 10:20 – 11:05 AM MST
Location: Phoenix Convention Center, Arizona (Exhibit Hall – Poster Area 3)
Presenter: Bruce C. Trapnell, M.D., Professor of Medicine and Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, U.S.

Learning Theatre

Title: Autoimmune Pulmonary Alveolar Proteinosis (aPAP): Understanding the Disease and Patient Experience
Date/Time: Tuesday, October 20, 2026, 12:30 – 1:15 PM MST
Location: Phoenix Convention Center, Learning Theatre 4
Speakers: Bruce C. Trapnell, M.D., Professor of Medicine and Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, U.S.; Eric and Karli, patients living with aPAP

About Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Autoimmune PAP is a rare lung disease characterized by the abnormal build-up of surfactant in the alveoli. Surfactant consists of proteins and lipids and is an important physiological substance that lines the alveoli to prevent them from collapsing. In a healthy lung, excess surfactant is cleared and digested by immune cells called alveolar macrophages. Alveolar macrophages need to be stimulated by granulocyte-macrophage colony-stimulating factor (GM-CSF) to function properly in clearing surfactant, but in aPAP, GM-CSF is neutralized by antibodies against GM-CSF, rendering macrophages unable to adequately clear surfactant. As a result, an excess of surfactant accumulates in the alveoli, causing impaired gas transfer, resulting in clinical symptoms of shortness of breath, often with cough and frequent fatigue. Patients may also experience episodes of fever, chest pain, or coughing up blood, especially if secondary lung infection develops. In the long term, the disease can lead to serious complications, including lung fibrosis and the need for a lung transplant.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim inhalation solution (molgramostim), is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via a proprietary investigational eFlow^® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of molgramostim. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261012229402/en/

Media and Investor Contact:
Savara Inc.
Temre Johnson, Executive Director, Corporate Affairs
ir@savarapharma.com

Source: Savara Inc.

Key Terms

open-label treatment period medical

An open-label treatment period is a stage after a controlled clinical trial when patients receive the study drug and both doctors and patients know what treatment is given. It matters to investors because it extends observation of safety and real-world effectiveness, can provide early commercial uptake clues, and may reveal longer-term side effects or benefits that influence regulatory approval and market prospects — like a public demo after a private test drive.

diffusion impairment medical

A reduction in the lungs' ability to move oxygen (and to a lesser extent carbon dioxide) from air in the alveoli into the blood across the alveolar-capillary membrane; it is usually measured by a decreased diffusing capacity for carbon monoxide (DLCO). Diffusion impairment happens when the gas-exchange surface area, membrane thickness, or capillary blood volume is abnormal (examples include interstitial scarring, emphysematous destruction, or pulmonary vascular disease) and commonly causes low oxygen levels during rest or exercise. It is distinct from ventilatory problems (airflow obstruction or restrictive lung volumes) because the primary defect is impaired transfer of gas across the lung membrane rather than reduced air movement or lung expansion.